KDR is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain KDR status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [4].

KDR is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain KDR status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [4].

KDR is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 1 is closed. Of the trials that contain KDR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 3 are phase 2 (2 open) [4].

KDR is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KDR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

KDR is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and gastric adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and gastric carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDR is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains KDR status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

KDR is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains KDR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDR is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDR is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KDR status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KDR is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KDR is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].